Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q92888
UPID:
ARHG1_HUMAN
Alternative names:
115 kDa guanine nucleotide exchange factor; Sub1.5
Alternative UPACC:
Q92888; O00513; Q6NX52; Q8N4J4; Q96BF4; Q96F17; Q9BSB1
Background:
Rho guanine nucleotide exchange factor 1, also known as a 115 kDa guanine nucleotide exchange factor or Sub1.5, plays a pivotal role in cellular processes by regulating RhoA GTPase activity. It functions as a GTPase-activating protein for GNA12 and GNA13, and as a guanine nucleotide exchange factor for RhoA GTPase, facilitating the regulation of RhoA GTPase by guanine nucleotide-binding alpha-12 and alpha-13 subunits.
Therapeutic significance:
Linked to Immunodeficiency 62, a primary immunologic disorder characterized by recurrent severe respiratory infections, Rho guanine nucleotide exchange factor 1's involvement in immune system regulation highlights its potential as a target for therapeutic intervention. Understanding its role could open doors to novel treatments for antibody deficiencies.